Canaccord lowered the firm’s price target on Rhythm Pharmaceuticals to $77 from $79 and keeps a Buy rating on the shares. The firm said its 2Q24 top line was largely in line with consensus; the bottom line was up due to a one-time gain of $8.9M on settlement of the forward contract associated with the issuance of convertible preferred stock this quarter.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RYTM:
- Rhythm Pharmaceuticals reports Q2 EPS (55c), consensus (71c)
- Rhythm Pharmaceuticals Reports Second Quarter 2024 Financial Results and Business Update
- RYTM Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Rhythm Pharmaceuticals Announces European Commission Expands ▼IMCIVREE® (setmelanotide) Marketing Authorization to include Children as Young as 2 Years Old
- Rhythm Pharmaceuticals announces expansion of IMCIVREE marketing authorization